1,721,311 research outputs found
Gestione di farmaci biologici ad alto costo in reumatologia e utilizzo di predittori di risposta: il modello dell'anticorpo monoclonale anti-CD20 (Rituximax) nell'artrite reumatoide
No full textRisk of thrombosis in sjögren syndrome: The open question of endothelial function immune-mediated dysregulation
No full textComment on: Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis: reply
No full textInterleukin 1 receptor antagonist therapy-induced thrombocytopenia in adult onset Still's disease
No full text
Rituximab monotherapy, rather than rituximab plus antiviral drugs, for initial treatment of severe hepatitis C virus-associated mixed cryoglobulinemia syndrome: comment on the article by Terrier et al
No full textRituximab as possible first-line therapy for glomerulonephritis in HCV-related mixed cryoglobulinaemia
No full textAssociation between bone marrow B cell clonal expansion and glomerulonephritis in type II mixed cryoglobulinaemia
No full textSjögren's Syndrome-Associated Lymphoma
No full textSjögren's syndrome (SS) is an autoimmune systemic disease characterized by B-cell lymphoproliferation and an increased risk of B-cell non-Hodgkin lymphoma (NHL) development, mainly of the mucosa-associated lymphoid tissue (MALT) type, which impacts survival and mortality. MALT lymphoma arises from chronic inflamed tissues through a multistep process in which a local, chronic, antigenic stimulation, together with a predisposing genetic background and with additional proliferative stimuli provided by the local molecular and cellular milieu of ectopic lymphoid glandular tissue, allows the emergence of B-cell clonal expansion and its possible evolution into overt malignancy. A complete assessment of SS always includes salivary gland biopsy. Imaging may be helpful for a noninvasive assessment of lymphoproliferation but it cannot substitute biopsy. New therapeutic B-cell targeting strategies are emerging to treat SS-related lymphoproliferation, ie, SS itself
- …
